<SEC-DOCUMENT>0001144204-12-064625.txt : 20121123
<SEC-HEADER>0001144204-12-064625.hdr.sgml : 20121122
<ACCEPTANCE-DATETIME>20121123060600
ACCESSION NUMBER:		0001144204-12-064625
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20121123
FILED AS OF DATE:		20121123
DATE AS OF CHANGE:		20121123

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		121222334

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v329154_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of November, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <B>000-51310</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>XTL Biopharmaceuticals Ltd.</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>85 Medinat Hayehudim St., Herzliya </B><BR>
<B>Pituach, PO Box 4033,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Herzliya 46140, Israel</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Wingdings">&#120;</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes <FONT STYLE="font-family: Wingdings">&#168;</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-<U> N/A </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. dated November 23, 2012 is hereby incorporated by reference into the registration statements
on Form F-3 (File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on March 23, 2007, October 30, 2007 and August 15, 2008, respectively, and the registration statements
on Form S-8 (File No. 333-148085, File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on December 14, 2007, January 18, 2008, and October 28, 2008, respectively.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>XTL Biopharmaceuticals Acquires Stake
in Proteologics Ltd. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">Below&nbsp;is
an English translation (from Hebrew) of an immediate report by XTL Biopharmaceuticals Ltd. as published on the Tel-Aviv Securities
Stock Exchange Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Herzliya, Israel
&ndash; November 23, 2012 &ndash; </FONT>Following the Company's announcement earlier today, regarding the acquisition of shares
of Proteologics Ltd. (hereinafter: &ldquo;<B>Proteologics&rdquo;</B>), which represent approximately 31.35% of its issued and outstanding
share capital, the Company hereby announces that following such acquisition, the Company has sent to Proteologics a letter requesting
that the board of directors of Proteologics will utilize its power and authority and appoint Mssrs. Efri Argaman and David Grossman
as members of the board of directors of Proteologics as well as a request that until the fulfillment of the Company's request for
the aforesaid appointment of directors, Proteologics will not adopt any resolution or execute any transaction, which is not in
the regular course of business of Proteologics.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; margin-left: 1.75in">Respectfully,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white; margin-left: 1.75in"><FONT STYLE="background-color: white">XTL
Biopharmaceuticals Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About XTL Biopharmaceuticals, Ltd. (&ldquo;XTL&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">XTL
Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical
products for the treatment of clinical unmet needs. XTL is focused on late stage clinical development of drugs for the treatment
of multiple myeloma, schizophrenia, and hepatitis C. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">XTL&rsquo;s
lead drug candidate, rHuEPO, for the treatment of multiple myeloma blood cancer, was granted an orphan drug designation from the
FDA. rHuEPO has been approved for marketing by the FDA and has for many years been sold for billions of dollars across the world
for the treatment of severe anemia. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL is a public company traded on the Tel
Aviv Stock Exchange (TASE: XTL) and its ADRs are quoted in the US on the Pink Sheets (OTC: XTLBY).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations, XTL Biopharmaceuticals
Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +972 9 955 7080, Email: ir@xtlbio.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cautionary Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of the statements included in this Form 6-K may be forward-looking statements that involve a number
of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained
in the Private Securities Litigation Reform Act of 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-weight: bold; text-align: justify; text-indent: 0">XTL BIOPHARMACEUTICALS LTD.</TD>
    <TD STYLE="padding: 0; font-weight: bold; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 35%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Date: November 23, 2012</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">By:</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; border-bottom: Black 1pt solid">/s/ David Grossman</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Name:</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">David Grossman</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Title:</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Chief Executive Officer</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``[`(L#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^[#4O$_PW
MT*Y33]7UWP?H^HLH*VFJ:KH^FWI#="T<TL<AR.0<CC&W@BOPD_X+B?\`!4KQ
M;_P3X^"OPRN?V=-&\">(OB3\8O$NI:-H_CG5K?2_$GA7PMI^A0@RR)#Y\BZY
MK;NWE1V[%A$R-(6<L"/%?^#CK_@G/K?Q_P#@K:_M=_!)_$4'QA^!&E2)XLTG
M0-1U+3W\7_"_#/K)D$3`-+X;C#7:+&@_<[A)MVDO_-]_P1_\<?`?]IW7=7_X
M)N?MNKJ/B/X+_';5E\3_``6\577B-M-\2_#3XR+P3H.N89B_BZ,?\(UMY#2'
M:"H;*_LW!'!F48S*5QCBI//Z62/GXDX7C&TN1;6DY>]!KWU[J;2LVV^4_,>(
M^*<UPN-_U?262O-VE'B*4FDTFGM%)W>D9/FBTF[<J4C^C;_@A%_P6"^+_P"W
M?KWQ>^$/[4F@^`W\8_"[PWI?C&U^)7AW0M*\+Z5J&D:YK9T,Z/K.@J?*T*96
MP06PLB%D=P"`/Z3+'Q?\+]4O8+#3O$G@?4=0G'^BPV6K:+?WS'J=D:32S$YZ
M`@Y.1@X-?Y]__!7:U_9E_P"":/@N?_@G)^P_/K=IXN^(%UI'C;]K'XK7GB0Z
MEX[OM*T10W@;X8MK9`/AXG/_``DY`!Q@$G+$#]&?^#=3_@FIXPM/AAXM_;K^
M+4OB&7Q1X[\'^)_"/[.N@^)-8U;&F:%K&C#0YO&K;G`5?%^"GF<A4\QQ\RC'
M5Q=P3P_B,I_UZPTGPYE&=5+<.\,N"<[*2IN7QVC'3VE[7Y97:BV[3P[Q)FJQ
M,N'\7)9YFL+OVCEI9)?%)*UK)[):Z:V/Z\?^$V^$V/\`D<_AW_X/O#&?S\S-
M-_X3SX0C_F=?AN?^Y@\+_P!9J_SR-?\`^#>C_@K=J'B/Q3?PVN@+;:GXD\3W
MEH3\5M6Q_9FN:OOP<D`'RP9"#_!\QRM?CW^TK\&OCM^R/\7O%'P)^,_B/6].
M\?\`@\:6=7M=)\8ZSJ>F;==!(P00"""#G&.#@]*WR+P?R#B#_9<KX_I.:@IR
M@J7OQT3:OSMI)Z7MV2U.?,_$/-\J=L9PO)*]D[Z.SBEJXM/T5VE=[79_K=#Q
MY\(,'_BM?ASGC@Z_X7'Y'S_Y?EBC_A._A#_T.OPX'_<P^%_S_P!?7^;U\-_^
M"#W_``5*^+?@#PC\2_!L>DW7A+QQX<TOQ+X?N;OXEZOIVJ+INNHL@5ESE6\M
MA(0W)5@XPI&?SB_:]_9R_:0_8I^*NL?`KX^ZYK.C^/+;PYI?B?[+H_C'6=3T
MLZ7KAQHF"I`Z@CD\$8IY?X/</YIC)X/!<?4ZF;4U).E&";?LM)1O[2VZ2=XW
M3>KN@Q'B'FV%PL,7B^&)0A.4;2<G97Y;-MQOI?6R;ZWM9G^N;9IX=U:V@NK&
M'1]1TZ<?Z/=6JZ9>Z>>.#'(@`;/<1EN1C.>*T_[(TOG&G6/`X/V2#U`_N5^=
MG_!(B>>;_@FS^QO-<3SW4W_"D?"Q>>ZG+,_R2XR>1@8X!&>HSS7Z1\[7QUVD
M#ZGITK\.S#"/"8S,<$IM^SJSHRFMY.$W2<[=_<<E?77S/TS+\6\5@Z>,VYXQ
MG97T;2:BMEULVM]M7J<?%?>$Y-2_LO?X?.L[59]-W:8UZ#U($*EF+;<'`7C.
M#STVFT;348,-/LBJ;P1]FBP23@%AM(.,]QU'O7\V_@2\OQ_P7%\4V[ZAJ9@$
M.JAK;[6#IN1H7+;<G)SDXSUXXZU_1S<>*?#EE="QO/$&CVNH$#%K=:II<5\O
MJ#`T@(YS_"1C//6OLN,^!:W".)R2A3Q]3.?[>X7R+B/]W3D_9^WIJ2B^5R3=
M-QBM;:JZW=OS?P\\2*'&.'XGQ-7!PR)Y%Q1G?#+]I44'-T)P?/:33O-J\N^F
MG>\VDZ808ET^R#!<AOLL6>"#UVYZ9'T&:P#>^$/[6.D";P\-7\I0+$MIQOMP
MQG]SGS=Q/&2GX]ZZE2C`$,K*$(+J=RY8D``@D'K@8^N,"ORFF_8!\7S?\%!3
M^UV/BW'_`,(X)_M(^'I1_O?V`="!\S&PL5^8C=][@<\#P<BP&7X]9FLRS%Y6
MZ>&J58/DG-UJT$N6FW'X>?1WMUZZGT?%.=YSEL,IEE>7+.(U\^I4YOVB2A">
M]2.MFXZKFNUI:Y^JPT;3<#_B6V)X'/V6WY]_N&E_L;3?^@;8_P#@+;__`!%:
M6](T&]@H50&9C@#CJ3P/?/2N<_X2KPJ;K[%_PD^@?VAC_CV_M?2OMV/3R/,W
M^V-F/?'->1"C5J)NG3J5%'=PA*27:[2=KVZV/JIXZE3<56KPI3DDU&I4A!O:
M]E*2;5[+:WWFI_8VE?\`0-L/_`2'_P")K0C78BI_=&T?0<#\Q2JZ,`5=6!Z%
M6!!^A!(-.K-Z.ST:W3W^XV332::::NFG=-=TUHT8.I:/IVJZ;=:3J5K#>V-_
M!)9W=M<`217=G(&5XY%(Y7]X_'RX+9#`X-?YG/\`P6=_8"\0_P#!-K]M*S\?
M_"HW.A_"GXE>*)/B3\%]>MF7?X0\51ZT-?US1"%9RG_",:Z8YX5?#-!+#(54
M.!7^EEXK\6^'_!/AG6O&'B?4+?1_#?AS2M1UG5]4NV$=EING:5&TTTLI.-N(
MU9R!DLR;$YVX_P`R?_@I_P#MM_$O_@K3^W5I'A/X7P:EJ7P_M_&3_"?]G+P0
M,_\`$QDDUPZ(WC<Y/7Q:QS@YVX"CA1C]P\"XYK3S_'8F*<>'U22XE<K*E*"2
M4(Q[RWV3LKWUE$_,/%/ZH\JY6E+-DTZ48J\TNMTEHM^7?7F:[&=_P3,_8\^(
MO_!6_P#;RN+KXN>*=3\2^'M+O-*^)W[1WC75+HMJVO:66VC1,("0/%9'_",L
M<;43,CE4#,/].CPMX4\.>!O#.B>$/"VFVNC^&_#.E:?HVCZ3:0+'8Z?I^DJL
M<,,0`"J$1%4$G+.IEY;<:_RO_@%\7OVA_P#@CW^WK;:KXETO4-(\9_"GQ$OA
MKXN_#];[.F>+O`>N;7UET=&!UXCY7BE3E65&C8$;E_U!O@3\:?`/[1?PC\"?
M&CX;ZS!KG@CXB^'--\1Z'J%LV1+!,%<\9XV.IB93CA0PR'%=?CS0QOUW*\9!
MM\&J-N&7!KV4&W%OF4?M2O:-VXV3V=V_.\*_JL<-F6&F^7.M.9S^-PTC;6S6
MOO-7]+K;V('(CZ\JV<]^3UK_`"[_`/@X$_Y2E_M*?]<O"G_H-?ZB&,>6/0-^
M')_^M^8K_+O_`.#@/_E*9^TI_P!<O"O_`*#7/]']K_6O-[M6?#6(:3VNVMD^
MK^\]#Q25LDRZ^_UB";\^6'YO\3_1%_X)V_\`)CW[*OO\$_`>??\`XD\?^`_*
MOX*?^#FS_E*%XT_[([X"_P#3(M?WJ_\`!.W_`),=_91_[(IX#_\`3)'7\%?_
M``<U_P#*3KQI_P!D<^'_`/Z"*Z/!FS\4,ZO9KEXBM?7KI:_H[?@<OB"FN$\J
MUW=%_?&&GY_B?W`_\$@O^4:?['7_`&1/PM_Z!)7Z2Y(+GK@,<?3I7YN?\$A2
M/^':O['0SS_PI/PKQ_VSDK](LC+\CHWY?YS7XSGJOQ#G.ET\;B4__"NK?\#[
MW)7_`,(N5V>OL*>VZ?)"[^_<_CR_:3\<_%'P3_P54^),GP3M;2\^*GBW5]+\
M%>$4OAE;+4M>T0$ZNP/RL,'Y@>&!^;@U]W3?\$5/'/BK1[OQ5XV_:T^)^J?&
M/40+V\UE;G/APZH1_!;G$Q7L,)NR"`I&37BVC:=I]_\`\%S]5:^!V6>I/?V0
MN>3_`&DNA$X4<#)'W0,#.!Q7]1"JH[$`#L#U`&?Q%?TSXH^(&?<'T?#BAPXJ
M>33EX:\-1K5%0H5*F(IQC.<:3G5IU'&GSRF[0LTYRY7&[O\`QUX/^%N0\=XK
MQ6Q/%=2>;1_XB;Q&HPC5G3C2<FH\UHR24DK6NG:RNFM5_-Y^P#^T_P#'K]GW
M]I[6OV%/VG/$%SXMA2Y%MX$\0:K=2ZEJEE?J5;1Q_:JX\W1?%$0<VJ3(S)/A
M?D#R9LS^-_'+?\%O(/"'_"9>+U\('3"?^$4&M:I_PC88^!\EAHP_<[L\AAB/
M/.`O`\P_;80'_@L1\!&T/>+XW/@-[W[.NU\#)RPS]X\G`]<CK753L6_X+NV[
MKU;1`P'/4^!01[]3_C7V-')\EK8G,.*JV6TZ=3C3P'SWB6K3@E&E3XDM%5*T
M*;3]G'G3L]G;=N[?Q+S?.<'ALOX+Q6:2S?*N"?'?A_AOAR7,_:?ZO+7V56::
M<W!1M*[\DK)7[_\`X*&?M@_'7XE?M`:+^PG^RAJ<V@^(=2N!:>//%^F,7U6/
M4%C)71I)9&?^P]$6-L7%P&_>-@D[=N;Z_P#!$34G\+C5[O\`:E^*TWQ;^R"[
M;6([X?\`"/+JIY+!65=?,8&,N;E6!.WRR17A?[!H^V_\%=/VBY_%0SX@MKOQ
MZ=%^U<DL.5QV)'AX`J.>?7-?T]N?F?>653]Q@,[54'.0,#))&.YYZY%?F?B#
MQ-F_A+_JGP?P.H9,JO"O#_$7$==T85I\0XC/82J3=1U8SC[.$()0A&UKRA:,
M>2WZQX<\'Y;XU?ZW<:^(+GF[CQ1G_#/#-*-6=)</9%DM10IKW'#WYRO*\D^9
MV;O=M_SM_L#_`+6WQ]^!_P"TU<?L(_M8:I=^)=0.H0:3X%\::O.S:K)>F5&T
M=4U5MC:[I/BJ,-]E9E66*X"HX*&2)OZ,SNSQMQ[YS7\U'[=PL(/^"OO[$[Z/
M_P`A9_$_PC35S",!H#\2+1)VE'HT9<MGD`G/M_2Q7R'C#ALKK/@CB?+LKAE.
M*XMX3PN:YQAZ2Y:$\QIUZN'JUZ4-?9JK&,9.*;7VM:DIRE]_X!8S-Z.&X]X2
MS+-7FN#X%XSQ/#F05YM.<,EHX6A6PE*<T_>E%SGJ];WZ6M_'K_P<J_\`!0WQ
MOHGAVU_8'^`6D^-[C6?&.G)J_P`=/$_A_1]7$>E^%FP^B^"AK$:^6K^+I&(D
M*E@R(@##G=X#_P`&QG_!-V^O_$^O_MY?%[PC<Z;9>&/[1\&_`C2=?L/L+K?A
ME_X2'QH(\@Y;F%&((61@X#JNT_VM7GA'PGJMQ/>WOAC0+Z]N,?:+J]TC3;UW
MP!Q(\\?F-]<DG.6)[:5EI]GIEK%8V-K;Z?:VZ_+;65J+*R!Z$+&B%`/H6R2"
MU?-T./7@N"*G"&499&@JK4JN(YE&I-OEYKM)2NXI0C)RE)1M_+%+],?"?UGB
M!<08S,7-12Y:=K))+16E>/*FM?=WUU]Z_P#)+_P<U?\`!-NY^)_@;0OVY/@_
MX5GU'X@?#BS3PS\7M*T>TSJ7BOP"P4:+K#GDE_"$@=L[1^[>/"[\D?&?_!MC
M_P`%`_'GP<\?C]AKXQZ'XWM_AI\3KO\`MCX*:_JOAW68]-\+>-I&43:$KD$K
MH/BM?WD#90">.-6D2)Y"?[K;BTMKZ!K:[BANH)>L%RH*L<`X&=V6[GOGH>IK
M!C\$^$K>2&:V\*^&K>XM\BTN;?0M*1[,X_Y9D1%E(SQLQSZ=:TH^(<GP1_J=
MG&6?VO"-_8U5*TZ&D7#V:E%I.G*_*G[KBHQDI+FNZO"=N(8\0X3,/9N22G3L
MN5II)IVLFGMLKO5]#K5'#_[I_`D=17^85_P7W\*^,=1_X*@?M*7VE>#_`!=J
MFG^5X5'VS2_#FKZGIS9C"Y)C&PDY^8H-A/W<#!'^GP-N#R3UR>>_MTSCT%<C
M?^$_"FIR_:+WPWH%_++R;B\T;3+PL.VYY8F=A]&.<=<GGS.!.,UP7FTLW_LU
M9MS49TE2ORI<UM=-4U:R5K>C/1XGX>7$F$AA)24>2:FF^CC9Z=+NS=OS/EK_
M`()[0W5M^Q%^RW;W-O-;3)\$_`7GV]Q"5=7_`+#A+*PQ@$[@<9.5V\?-S_"9
M_P`')?A;Q9KW_!4'Q9<:9X.\7ZU8'X.>`=UUI?AS5]2T_.SG+1@Q@@]=@VDG
MY1CI_H\06L5I%#!;1PVUO",I;P#:J\<8`50.H/(!/K6)?>%O#&JS_;-1\.:+
MJ5P1@7=[I>G7CXY_CDC=\]>>OO73P=QH^%N)*O$BRY5?:2K2]C*:@K5Y<[BW
M:]E&\==.5/J<F?\`"O\`;F4PRC^T'!PY+3L[IQ2BM$WIHG9+>R[G^9C\(/\`
M@LG_`,%6?@/\+_!/P>^'%W?Z=X!^'OAO2_#'A.TO/A1J^I:G9:5H0V@.>K#8
M-I##&W"\BO21_P`%[_\`@LI_T&]1'O\`\*</]!FO]'L>!/!N<CP?X5^AT'2_
MZP8/?M_]<_X0/P9_T)WA/_PG](/Z?9^?I7VN)\5>%L5)SEX><..3ESR=XW;;
M4FVU'=W;N^Y\]AN`N(,+'EAQ5->[9)1F^5<JBFDW>ZLM'T[;K^#[]D_XH_MH
M?M`_%KPI^U)!X?UCQ3^T5IFWQ[K,#>&CI,?B'2M&`1M#VM@`/H#;$!Y/'<C/
M]!\/_!=/X(6?AHC7/A5\4]-^)=O;_9KOP&VC$@:IL`V?VUD1[-WS?ZO(&5!!
M^8?M[8^'_#^EMYFF^']$L)""OFZ?IFFV;$'@AA'"A/ODCTS@8KD;OX4?"R_U
M=_$5_P##OP=<:S&%']J3^'-*>_Y)'^N:%G]"3NR#]!79Q%XN<$\;/+/]9O#N
M+I9)AH8;(/[!SV5"HZ<+J5*JG3Y94FGI&')[*7M>1VJ>[^3</^"/B!P+/B;%
M<&>*$(/B7B>MQ'G\,_R!5(1]KJZ>'E*=2I[JT4Y2E)QC'FE>+O\`@9_P3_\`
M@5\9/VHOVLO$G[?WQ_\`"U[X4TBUN'O/AOHNH6?V&YU#4W1]!T(JI)9M"\,>
M'581L<L\K#)))-49]-U7_A^G!?#2-3_L_P"S'&I_9O\`B6\>!B`OF?WN@W=0
M>=W>OZ/8+2*WMX[>TB2WBB4F.*!0%`88R>ASCI^G<5!'H^G+>)>'3K'[2$)-
MZ;2,WI)Z`3%?,`!(&`<8X`/;Q9>,V,Q>;YSCI99"GEF;<)U.$>'N'N=\O#60
MSY)1C&<HISE!_')QBW.=K7?+'VL/X`8.AD/"^5O-)3S7*.+H>(O$O$2IM3XC
MXAN^;F5WRTWKRI.T8*-K-M/^=O\`;^_9P^-?[-O[4?A_]O']G#P_J/BRR6Y^
MV?$?P[I$#:GJ=G?@F/76&CH=W]A>)O#X,4X1C+%,FX@"2(MZY'_P7<^`A\'F
M>Y^&/Q+/Q$-D,^!?L:%3J04CR_[9V%`ISNSDMD$9`.!^YL\-O<31I):BXCDC
M`:5B<!`,'*@[3MQ@#KQG&17GH^#WPP.I-K1^&_@G^TR-J7O_``CVE+/C=@L7
M>%CNZ@=23R,<8FEX@<-YKE&4X+CSA&IQ!F614Z='#9_0SNKD]:>%@HJ&$KPC
M&LJL*5K0G+EER<UG&4JCJ:XCPHXPR'B#B+-_##CQ9!E'$'M*W$7#F?Y&L^I0
MSV4=<3D4FZ;H\][R@N>/-:[<4N7\#/V$/V??CO\`M:_M<-^WI^T7X?N_"GAW
M0;Z'4O`'AW5+-K2:^U.%MWA]M$W%G;0?"XC81M(=TLG4L0:_I3P/0?E6186T
M4!2*")(+6)6$-NB[5C.X')Y)+9!!))R<@'`P-1D))/'^1]*^/XUXQQ'&6;+%
M_P!G4LFRK`48X#),FHSE.GE^`I2<HTU-VYY3FW*<^6#E9+EC&,4OT3PR\/,+
MX=Y!4P?U^6=9YG.+EG?$^?U%RSSK.\5"$<1C'!?!#EA&G3A=\L8W>K:)**;L
M'JW_`'VY_FU&T>K?]]O_`/%5\@?HUEM;3L)L'J?T_P`*?3=H]6_[[?\`^*HV
MCU;_`+[?_P"*H`=28'H/RI-H]6_[[?\`^*HVCU;_`+[?_P"*H`=13=H]6_[[
M?_XJC:/5O^^W_P#BJ`'44W:/5O\`OIC_`#-.HLNW]?TD`8`Z#%)@'.0#GKP.
M?K2T4DDK625MK=/3L`F!Z#\J7`]!113`3`]!^5&!Z#\J6B@!,`=`!^%+128'
&H/RH`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
